carboplatin + nab-paclitaxel + paclitaxel + pembrolizumab

This is a combination therapy consisting of three chemotherapy agents (carboplatin, nab-paclitaxel, and paclitaxel) plus pembrolizumab, an immune checkpoint inhibitor. The FDA approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC)[4]. This approval was based on the KEYNOTE-407 trial, which demonstrated superior overall survival with this combination compared to chemotherapy alone[4]. The combination works through multiple mechanisms: - Carboplatin is a platinum-based chemotherapy that forms DNA crosslinks, preventing DNA replication - Nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are taxanes that stabilize microtubules, preventing cell division - Pembrolizumab is an anti-PD-1 therapy that helps the immune system detect and fight cancer cells In clinical trials, this combination demonstrated a 36% reduction in the risk of death compared to chemotherapy alone in patients with metastatic squamous NSCLC[4].